Trial Profile

Phase 1, Randomized, Double-blind, Placebo-controlled, Staggered, Parallel, Single and Multiple Ascending Dose and Food Effect Study to Evaluate the Safety and PK of Oral SAT-3247 in Healthy Volunteers and Participants With DMD

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SAT 3247 (Primary)
Indications Duchenne muscular dystrophy; Facioscapulohumeral muscular dystrophy; Muscle injury
Focus Adverse reactions; First in man
Sponsors Satellos Bioscience

10 Oct 2025 According to a Satellos Bioscience media release, company presents tolerability and initial efficacy data at the 30th Annual Congress of the World Muscle Society in Vienna, Austria.
10 Oct 2025 Results presented in the Satellos Bioscience media release.
29 Sep 2025 According to a Satellos Bioscience media release, the company announced that it will present two scientific posters at the 30th Annual Congress of the World Muscle Society (WMS), taking place Oct. 7-11, 2025, in Vienna, Austria.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com